Recursion Pharmaceuticals appointed Fred Hassan as Chair of its Board, effective October 31, 2026. Hassan brings over 40 years of pharmaceutical experience, including leadership roles at Schering-Plough and BridgeBio Pharma, known for driving drug approvals and commercial success. His expertise is expected to guide Recursion through clinical development and market launch phases, enhancing its AI-enabled drug discovery platform. The company aims to leverage his leadership to accelerate innovative medicine development for patients with unmet medical needs.
Recursion Pharmaceuticals' stock price on Pluang is USD 3.82 as of Nov 03, 2026 04:11 WIB, showing a 5.21% decline in one day. The company holds a market capitalization of $2.43 billion on the platform. All current Pluang orders for RXRX are buys, indicating strong investor interest despite the recent price drop.
